On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29030331.
- Also identified by DOI 10.1158/1078-0432.CCR-17-2332.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The larger fraction of patients treated with immune checkpoint inhibitors remain nonresponding eventually. Combination of checkpoint inhibitor and costimulatory antibodies is thought additive, but for such effect, they may require to be given in the right sequence. <i>Clin Cancer Res; 23(20); 5999-6001. ©2017 AACR</i><i>See related article by Messenheimer et al., p. 6165</i>.
Medical subject headings
- Antineoplastic Agents, Immunological
- Antineoplastic Combined Chemotherapy Protocols
- Molecular Targeted Therapy
- Neoplasms
- Programmed Cell Death 1 Receptor
- Receptors, OX40